+Compare
SBIO
ETF ticker: NYSE ARCA
AS OF
Loading...
Price
Loading...
Change
Loading...
Net Assets
81.36M

SBIO ALPS Medical Breakthroughs ETF Forecast, Technical & Fundamental Analysis

Category Health
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for SBIO with price predictions
07:00 PM EST Nov 26, 2023

SBIO's Stochastic Oscillator is sitting in overbought zone for 4 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SBIO broke above its upper Bollinger Band on November 03, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SBIO entered a downward trend on November 15, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SBIO's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 22, 2023. You may want to consider a long position or call options on SBIO as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for SBIO just turned positive on October 31, 2023. Looking at past instances where SBIO's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF ETF is 1.22B. The market cap for tickers in the group ranges from 59.42M to 4.83B. IMVT holds the highest valuation in this group at 4.83B. The lowest valued company is ACRS at 59.42M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was 2%. For the same ETF, the average monthly price growth was 9%, and the average quarterly price growth was -19%. ALT experienced the highest price growth at 22%, while PDSB experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was -15%. For the same stocks of the ETF, the average monthly volume growth was -4% and the average quarterly volume growth was -23%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 84
Price Growth Rating: 57
SMR Rating: 94
Profit Risk Rating: 92
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
ALPS ETFPO Box 328Denver
Phone
855.724.0450
Web
www.alpsfunds.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NBNAX12.51N/A
N/A
Neuberger Berman International Sel A
CVGRX35.93N/A
N/A
Calamos Growth A
MRVNX11.30N/A
N/A
Mirova International Sustainable Eq N
OAZLX63.74N/A
N/A
Oakmark Select R6
GSRFX12.25N/A
N/A
Goldman Sachs Rising Dividend Gr R6

SBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SBIO has been closely correlated with XBI. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if SBIO jumps, then XBI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBIO
1D Price
Change %
SBIO100%
+0.38%
XBI - SBIO
92%
Closely correlated
-0.19%
IBB - SBIO
78%
Closely correlated
-0.30%
VHT - SBIO
55%
Loosely correlated
-0.52%
IHI - SBIO
48%
Loosely correlated
-1.06%
XLV - SBIO
44%
Loosely correlated
-0.51%